cyproterone acetate has been researched along with Fractures, Bone in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernier, J; Billiet, I; Bolla, M; Collette, L; Cutajar, CL; Dubois, JB; Kuten, A; Mirimanoff, RO; Pfeffer, R; Sternberg, C; Storme, G; Torecilla, JL; Van der Kwast, T; Van Tienhoven, G; Warde, P | 1 |
| D'Amico, AV | 1 |
| Heikkinen, AM; Honkanen, R; Komulainen, M; Kröger, H; Mäenpää, PH; Mahonen, A; Pallonen, H; Saarikoski, S; Salmén, T | 1 |
| Heikkinen, AM; Honkanen, R; Komulainen, M; Kröger, H; Mäenpää, PH; Mahonen, A; Saarikoski, S; Salmén, T | 1 |
3 trial(s) available for cyproterone acetate and Fractures, Bone
| Article | Year |
|---|---|
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Canada; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Europe; Fractures, Bone; Goserelin; Humans; Israel; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Prostatic Neoplasms; Risk Assessment; Russia; Time Factors; Treatment Outcome | 2010 |
Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial.
Topics: Aged; Alleles; Bone Density; Cholecalciferol; Cyproterone Acetate; Estradiol; Exons; Female; Fractures, Bone; Genotype; Hormone Replacement Therapy; Humans; Middle Aged; Polymorphism, Genetic; Postmenopause; Random Allocation; Receptors, Androgen; Time Factors | 2003 |
The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor alpha genotype in early postmenopausal women.
Topics: Androgen Antagonists; Cyproterone Acetate; Estradiol; Estrogen Receptor alpha; Estrogen Replacement Therapy; Female; Follow-Up Studies; Fractures, Bone; Genotype; Humans; Middle Aged; Osteoporosis, Postmenopausal; Polymorphism, Genetic; Receptors, Estrogen; Risk | 2000 |
1 other study(ies) available for cyproterone acetate and Fractures, Bone
| Article | Year |
|---|---|
Is long-term androgen suppression right for everyone with locally advanced prostate cancer?
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Chemotherapy, Adjuvant; Cyproterone Acetate; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Fractures, Bone; Goserelin; Humans; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Prostatic Neoplasms; Risk Assessment; Time Factors; Treatment Outcome | 2010 |